MX2014001767A - Metodos para reducir sintomas o condiciones causados por estres. - Google Patents

Metodos para reducir sintomas o condiciones causados por estres.

Info

Publication number
MX2014001767A
MX2014001767A MX2014001767A MX2014001767A MX2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A
Authority
MX
Mexico
Prior art keywords
stress
conditions caused
methods
ameliorating symptoms
fatty acid
Prior art date
Application number
MX2014001767A
Other languages
English (en)
Inventor
Yuanlong Pan
Delphine Tissot-Favre
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2014001767A publication Critical patent/MX2014001767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

La invención proporciona métodos para usar alcanolamidas de ácido graso para mejorar uno o más síntomas o condiciones causados por estrés, por ejemplo, pérdida de apetito, o para mantener y mejorar la ingesta de nutrientes y calorías en un animal bajo estrés o que haya experimentado estrés. Generalmente, las alcanolamidas de ácido graso se administran en cantidades de 0.1 a 1500 mg/kg/día antes, durante o después del estrés, preferentemente sobre una base regular o diaria como un componente de una composición alimenticia o como un suplemento dietético.
MX2014001767A 2011-08-15 2012-08-07 Metodos para reducir sintomas o condiciones causados por estres. MX2014001767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161575073P 2011-08-15 2011-08-15
PCT/US2012/049825 WO2013025399A1 (en) 2011-08-15 2012-08-07 Methods for ameliorating symptoms or conditions caused by stress

Publications (1)

Publication Number Publication Date
MX2014001767A true MX2014001767A (es) 2014-05-01

Family

ID=47715371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001767A MX2014001767A (es) 2011-08-15 2012-08-07 Metodos para reducir sintomas o condiciones causados por estres.

Country Status (10)

Country Link
US (1) US20140199267A1 (es)
EP (1) EP2744488A4 (es)
JP (1) JP2014525931A (es)
CN (1) CN103917230A (es)
AU (1) AU2012295432A1 (es)
BR (1) BR112014003445A2 (es)
CA (1) CA2846213A1 (es)
MX (1) MX2014001767A (es)
RU (1) RU2014110056A (es)
WO (1) WO2013025399A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262763A2 (en) 2008-03-04 2010-12-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compounds and methods of treating obesity
WO2014013497A1 (en) * 2012-07-20 2014-01-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fatty acid derivatives for use in a method of treating depression and associated conditions
JP6563218B2 (ja) * 2015-03-13 2019-08-21 ユニ・チャーム株式会社 ペットフードの製造方法
KR101997028B1 (ko) * 2018-11-30 2019-07-05 강원대학교산학협력단 각성 강화용 유산균 혼합 조성물 및 이의 용도
EP4070807A1 (en) * 2019-12-02 2022-10-12 Life Quality Institute, Inc. Agent for prevention or remediation of stress disorders and composition containing same
CN117143760A (zh) * 2023-07-12 2023-12-01 西南大学 一株能促进5-htp分泌及缓解抑郁的鼠李糖乳酪杆菌ky16及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
US20070155747A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CN101351495A (zh) * 2005-12-29 2009-01-21 欧加农股份有限公司 脂肪酸酰胺水解酶抑制剂
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JP2011521914A (ja) * 2008-05-19 2011-07-28 ネステク ソシエテ アノニム 動物による脂質吸収を抑制する方法
US20100190860A1 (en) * 2009-01-09 2010-07-29 The Brigham And Women's Hospital, Inc. Methods for selectively enhancing antinociceptive potency of local anesthetics

Also Published As

Publication number Publication date
US20140199267A1 (en) 2014-07-17
JP2014525931A (ja) 2014-10-02
CA2846213A1 (en) 2013-02-21
AU2012295432A1 (en) 2014-02-27
BR112014003445A2 (pt) 2018-03-20
CN103917230A (zh) 2014-07-09
EP2744488A1 (en) 2014-06-25
RU2014110056A (ru) 2015-09-27
EP2744488A4 (en) 2014-07-09
WO2013025399A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
MX2014001767A (es) Metodos para reducir sintomas o condiciones causados por estres.
MX2013002603A (es) Composicion de aceite y metodo para producir la misma.
WO2013153071A3 (en) A nutritional composition
WO2013049519A3 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
IN2014CN04115A (es)
MY166016A (en) Infant nutrition for improving fatty acid composition of brain membranes
EA201070419A1 (ru) Состав для регулирования метаболизма липидов
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
MX338245B (es) Metodos y composicioes para inducir la saciedad.
MX2015013033A (es) Metodo para preparar harina de grano entero altamente dispersable con un contenido mejorado de avenantramida.
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
MX2010004642A (es) Procedimiento para reducir el contenido en acidos grasos saturados de la grasa de leche, productos obtenidos y aplicaciones del mismo.
WO2013028555A3 (en) Methods for weight loss and ketogenic compositions
MY166855A (en) Device For Processing Plant Remnants
WO2011092473A8 (en) Novel compounds and their effects on feeding behaviour
MX2011012741A (es) Un suplemento que comprende grosellas negras o moras grandes.
MX344481B (es) Composiciones nutricionales a base de leche fortificada.
MY172574A (en) Dicaffeoylquinic acid-containing drink
MY174494A (en) Method for inhibiting pathogens using a nutritional composition
WO2010119424A3 (fr) Composition destinee a la regulation du metabolisme des lipides
MY169098A (en) Ready to drink beverages and methods of making thereof
WO2012021163A3 (en) Methods for enhancing the stability of foods, beverages, and cosmetics using natural products derived from non-allergenic proteinaceous sources
BR112012016054A2 (pt) Composições nutricionais compreendendo flocos de fruta incluindo ácido docosa-hexaenoico
MX2011007222A (es) Composicion nutricional para infantes.
WO2010072209A3 (de) Nahrungsergänzungsmittel auf der basis von pantothensäure